Divi’s Laboratories to manufacture API of MSD’s Covid drug Molnupiravir

Divi’s Laboratories Limited has been selected by pharma giant MSD (known as Merck in the US and Canada) as an authorized manufacturer for the active pharmaceutical ingredient (API) of the latter Covid-19 drug candidate Molnupiravir.

The Hyderabad-based API producer said that it is allowed to supply Molnupiravir API to MSD’s

Currently, Molnupiravir is being evaluated in a phase 3 clinical trial. MSD is developing the drug candidate in collaboration with Ridgeback Biotherapeutics.

Divi’s Laboratories to manufacture API of MSD’s Covid drug Molnupiravir. Image courtesy of Pete Linforth from Pixabay.

Last month, Cipla signed a non-exclusive licensing agreement with MSD for the manufacturing and distribution of Molnupiravir for the treatment of non-hospitalized Covid-19 patients.